vs
ESPEY MFG & ELECTRONICS CORP（ESP）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
ESPEY MFG & ELECTRONICS CORP的季度营收约是Protalix BioTherapeutics, Inc.的1.3倍（$12.1M vs $9.1M），ESPEY MFG & ELECTRONICS CORP净利率更高（23.1% vs -60.3%，领先83.4%），ESPEY MFG & ELECTRONICS CORP同比增速更快（-10.8% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-4.1M），过去两年ESPEY MFG & ELECTRONICS CORP的营收复合增速更高（21.3% vs -6.7%）
Espey制造电子公司是总部位于美国的制造商，专注于高可靠性电源、电力转换系统及专用电子元件的设计生产，面向航空航天、国防、工业及交通领域，为北美及部分国际市场客户提供适配恶劣运行环境的定制化解决方案。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
ESP vs PLX — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.1M | $9.1M |
| 净利润 | $2.8M | $-5.5M |
| 毛利率 | 34.7% | 49.4% |
| 营业利润率 | 25.3% | -51.1% |
| 净利率 | 23.1% | -60.3% |
| 营收同比 | -10.8% | -49.9% |
| 净利润同比 | 47.0% | -184.8% |
| 每股收益（稀释后） | $0.99 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $12.1M | $9.1M | ||
| Q3 25 | $9.1M | $17.9M | ||
| Q2 25 | $9.6M | $15.7M | ||
| Q1 25 | $10.3M | $10.1M | ||
| Q4 24 | $13.6M | $18.2M | ||
| Q3 24 | $10.4M | $18.0M | ||
| Q2 24 | $11.6M | $13.5M | ||
| Q1 24 | $8.3M | — |
| Q4 25 | $2.8M | $-5.5M | ||
| Q3 25 | $2.2M | $2.4M | ||
| Q2 25 | $2.9M | $164.0K | ||
| Q1 25 | $1.7M | $-3.6M | ||
| Q4 24 | $1.9M | $6.5M | ||
| Q3 24 | $1.6M | $3.2M | ||
| Q2 24 | $1.9M | $-2.2M | ||
| Q1 24 | $1.0M | — |
| Q4 25 | 34.7% | 49.4% | ||
| Q3 25 | 35.4% | 53.4% | ||
| Q2 25 | 39.3% | 62.5% | ||
| Q1 25 | 28.6% | 19.1% | ||
| Q4 24 | 23.2% | 78.7% | ||
| Q3 24 | 26.8% | 53.4% | ||
| Q2 24 | 27.6% | 29.8% | ||
| Q1 24 | 25.0% | — |
| Q4 25 | 25.3% | -51.1% | ||
| Q3 25 | 22.7% | 11.9% | ||
| Q2 25 | 27.4% | 7.5% | ||
| Q1 25 | 17.0% | -41.0% | ||
| Q4 24 | 14.9% | 39.6% | ||
| Q3 24 | 16.5% | 22.2% | ||
| Q2 24 | 18.4% | -18.0% | ||
| Q1 24 | 13.2% | — |
| Q4 25 | 23.1% | -60.3% | ||
| Q3 25 | 23.9% | 13.2% | ||
| Q2 25 | 30.6% | 1.0% | ||
| Q1 25 | 16.5% | -35.8% | ||
| Q4 24 | 14.0% | 35.6% | ||
| Q3 24 | 15.3% | 18.0% | ||
| Q2 24 | 16.3% | -16.4% | ||
| Q1 24 | 12.5% | — |
| Q4 25 | $0.99 | $-0.06 | ||
| Q3 25 | $0.76 | $0.03 | ||
| Q2 25 | $1.07 | $0.00 | ||
| Q1 25 | $0.63 | $-0.05 | ||
| Q4 24 | $0.71 | $0.10 | ||
| Q3 24 | $0.61 | $0.03 | ||
| Q2 24 | $0.73 | $-0.03 | ||
| Q1 24 | $0.40 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.8M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $53.2M | $48.2M |
| 总资产 | $85.2M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $17.8M | $14.7M | ||
| Q3 25 | $22.2M | $13.6M | ||
| Q2 25 | $18.9M | $17.9M | ||
| Q1 25 | $13.9M | $19.5M | ||
| Q4 24 | $8.0M | $19.8M | ||
| Q3 24 | $4.8M | $27.4M | ||
| Q2 24 | $4.4M | $23.4M | ||
| Q1 24 | $5.6M | — |
| Q4 25 | $53.2M | $48.2M | ||
| Q3 25 | $51.0M | $52.9M | ||
| Q2 25 | $50.8M | $49.9M | ||
| Q1 25 | $46.3M | $45.2M | ||
| Q4 24 | $44.8M | $43.2M | ||
| Q3 24 | $42.5M | $32.4M | ||
| Q2 24 | $41.3M | $28.6M | ||
| Q1 24 | $39.3M | — |
| Q4 25 | $85.2M | $82.3M | ||
| Q3 25 | $84.8M | $82.3M | ||
| Q2 25 | $79.1M | $78.5M | ||
| Q1 25 | $72.8M | $73.9M | ||
| Q4 24 | $60.2M | $73.4M | ||
| Q3 24 | $57.6M | $61.6M | ||
| Q2 24 | $56.5M | $91.5M | ||
| Q1 24 | $53.1M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.8M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $-4.1M | $1.6M |
| 自由现金流率自由现金流/营收 | -34.1% | 17.8% |
| 资本支出强度资本支出/营收 | 10.9% | 4.4% |
| 现金转化率经营现金流/净利润 | -1.00× | — |
| 过去12个月自由现金流最近4个季度 | $11.7M | $-13.6M |
8季度趋势，按日历期对齐
| Q4 25 | $-2.8M | $2.0M | ||
| Q3 25 | $5.7M | $-3.7M | ||
| Q2 25 | $2.8M | $-5.2M | ||
| Q1 25 | $11.5M | $-5.1M | ||
| Q4 24 | $5.4M | $4.0M | ||
| Q3 24 | $1.4M | $4.1M | ||
| Q2 24 | $3.2M | $-3.6M | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $-4.1M | $1.6M | ||
| Q3 25 | $4.4M | $-4.2M | ||
| Q2 25 | $915.3K | $-5.7M | ||
| Q1 25 | $10.5M | $-5.4M | ||
| Q4 24 | $4.5M | $3.6M | ||
| Q3 24 | $724.8K | $4.0M | ||
| Q2 24 | $2.6M | $-3.8M | ||
| Q1 24 | $379.1K | — |
| Q4 25 | -34.1% | 17.8% | ||
| Q3 25 | 48.7% | -23.7% | ||
| Q2 25 | 9.5% | -36.2% | ||
| Q1 25 | 101.8% | -53.0% | ||
| Q4 24 | 33.0% | 19.6% | ||
| Q3 24 | 6.9% | 22.4% | ||
| Q2 24 | 22.2% | -28.1% | ||
| Q1 24 | 4.6% | — |
| Q4 25 | 10.9% | 4.4% | ||
| Q3 25 | 14.2% | 2.8% | ||
| Q2 25 | 19.3% | 2.8% | ||
| Q1 25 | 9.3% | 3.0% | ||
| Q4 24 | 6.5% | 2.3% | ||
| Q3 24 | 6.4% | 0.5% | ||
| Q2 24 | 5.7% | 1.3% | ||
| Q1 24 | 12.5% | — |
| Q4 25 | -1.00× | — | ||
| Q3 25 | 2.64× | -1.58× | ||
| Q2 25 | 0.95× | -31.91× | ||
| Q1 25 | 6.72× | — | ||
| Q4 24 | 2.82× | 0.61× | ||
| Q3 24 | 0.87× | 1.27× | ||
| Q2 24 | 1.71× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESP
| ASC606 | $11.3M | 93% |
| Other | $855.0K | 7% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
